Product-related advice

• CMDh letter to MAHs of tenofovir disoproxil-containing medicinal products (February 2023, correction: June 2023)

• Q&As on the implementation of the outcome of the Art. 31 referral on angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (December 2021) [Tracked]

• Harmonised warning for ferrous sulfate-containing medicinal products on dysphagia and related bronchostenosis due to risk of aspiration (May 2018) [Tracked]

• Concomitant use of benzodiazepines/benzodiazepine like products and opioids (February 2018)

Deletion of interaction between broad spectrum antibiotics and combined oral contraceptives (COC)

• Public Assessment Report (March 2015) corrected in March 2016 [Tracked]
• List of ATC codes for which the change applies (January 2016)

• CMDh letter for MAHs for medicinal products containing active ingredients in the form of Mesilates, Isetionates, Tosilates or Besilates (February 2008)